X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA ABBOTT INDIA SHASUN PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 123.9 42.2 293.8% View Chart
P/BV x 8.5 10.5 81.0% View Chart
Dividend Yield % 0.2 0.6 36.6%  

Financials

 SHASUN PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
ABBOTT INDIA
Mar-16
SHASUN PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs946,015 1.6%   
Low Rs463,707 1.2%   
Sales per share (Unadj.) Rs214.21,236.9 17.3%  
Earnings per share (Unadj.) Rs5.3122.2 4.4%  
Cash flow per share (Unadj.) Rs15.8129.0 12.3%  
Dividends per share (Unadj.) Rs1.0035.00 2.9%  
Dividend yield (eoy) %1.40.7 198.7%  
Book value per share (Unadj.) Rs53.3521.2 10.2%  
Shares outstanding (eoy) m56.6221.25 266.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.9 8.3%   
Avg P/E ratio x13.139.8 32.9%  
P/CF ratio (eoy) x4.437.7 11.7%  
Price / Book Value ratio x1.39.3 14.1%  
Dividend payout %18.728.6 65.4%   
Avg Mkt Cap Rs m3,958103,296 3.8%   
No. of employees `000NA3.0 0.0%   
Total wages/salary Rs m2,1643,370 64.2%   
Avg. sales/employee Rs ThNM8,891.8-  
Avg. wages/employee Rs ThNM1,140.0-  
Avg. net profit/employee Rs ThNM878.3-  
INCOME DATA
Net Sales Rs m12,12726,284 46.1%  
Other income Rs m229504 45.5%   
Total revenues Rs m12,35626,789 46.1%   
Gross profit Rs m1,0093,665 27.5%  
Depreciation Rs m594144 411.1%   
Interest Rs m4158 5,124.7%   
Profit before tax Rs m2304,017 5.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-731,421 -5.1%   
Profit after tax Rs m3022,596 11.6%  
Gross profit margin %8.313.9 59.7%  
Effective tax rate %-31.735.4 -89.5%   
Net profit margin %2.59.9 25.2%  
BALANCE SHEET DATA
Current assets Rs m6,88414,446 47.7%   
Current liabilities Rs m8,4564,725 179.0%   
Net working cap to sales %-13.037.0 -35.0%  
Current ratio x0.83.1 26.6%  
Inventory Days Days6251 119.9%  
Debtors Days Days10820 549.9%  
Net fixed assets Rs m4,9701,113 446.6%   
Share capital Rs m113213 53.3%   
"Free" reserves Rs m2,87510,808 26.6%   
Net worth Rs m3,02011,076 27.3%   
Long term debt Rs m1,8170-   
Total assets Rs m13,34716,241 82.2%  
Interest coverage x1.6497.0 0.3%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.91.6 56.1%   
Return on assets %5.416.0 33.5%  
Return on equity %10.023.4 42.7%  
Return on capital %13.336.3 36.7%  
Exports to sales %46.40.6 7,539.7%   
Imports to sales %14.212.6 112.7%   
Exports (fob) Rs m5,622162 3,478.7%   
Imports (cif) Rs m1,7283,322 52.0%   
Fx inflow Rs m5,843268 2,180.1%   
Fx outflow Rs m2,1733,927 55.3%   
Net fx Rs m3,669-3,659 -100.3%   
CASH FLOW
From Operations Rs m3982,514 15.8%  
From Investments Rs m-1,635-800 204.5%  
From Financial Activity Rs m1,309-803 -163.0%  
Net Cashflow Rs m71912 7.8%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.6 7.9 45.6%  
FIIs % 17.6 0.1 17,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.1 231.6%  
Shareholders   20,750 18,270 113.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   SUN PHARMA  WYETH LTD  GSK PHARMA  FULFORD INDIA  DR. REDDYS LAB  

Compare SHASUN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; IT Stocks Top Gainers(01:30 pm)

After opening the day marginally higher, share markets in India continued the momentum and are presently trading in green. Sectoral indices are trading on a mixed note, with stocks in the IT sector.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - SUVEN LIFE COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS